JORGE E CORTES to Splenomegaly
This is a "connection" page, showing publications JORGE E CORTES has written about Splenomegaly.
Connection Strength
0.366
-
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51.
Score: 0.120
-
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54.
Score: 0.095
-
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800.
Score: 0.051
-
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7.
Score: 0.026
-
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7.
Score: 0.024
-
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877.
Score: 0.022
-
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64.
Score: 0.016
-
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002 May 15; 94(10):2738-44.
Score: 0.012